Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NYK1
UPID:
TLR7_HUMAN
Alternative names:
-
Alternative UPACC:
Q9NYK1; D1CS69; Q9NR98
Background:
Toll-like receptor 7 (TLR7) is a pivotal endosomal receptor in the immune system, recognizing uridine-rich ssRNAs from viruses or guanosine analogs. This recognition triggers TLR7 dimerization, leading to the formation of the Myddosome signaling complex, activating NF-kappa-B and IRF7, and ultimately inducing pro-inflammatory cytokines and interferons.
Therapeutic significance:
TLR7's role in diseases such as Immunodeficiency 74, COVID19-related, X-linked, and Systemic lupus erythematosus 17, underscores its potential as a target for therapeutic intervention. Understanding TLR7's function could pave the way for novel treatments for these immune-related conditions.